Rule 18: Devices Using Human or Animal Tissue, Cells and Derivatives Are Class III, with Article 1, Annex I 13 and ÜTS Fields

SUMMARY
Rule 18 is one of the special rules in Annex VIII of the Medical Device Regulation. It makes devices manufactured utilising non-viable or rendered non-viable tissues, cells or their derivatives of human or animal origin class III; the only exception is devices of animal origin intended to come into contact with intact skin only.
In this article we give, with verbatim quotations (unofficial translation), the full text of the rule, the scope provisions in Article 1 of the Regulation, the relevant definitions, Section 13 of Annex I, and the tissue and cell fields in the ÜTS product record.
For ÜTS registration of your device containing tissue or derivatives: Medical Device ÜTS Registration Consultancy
Contents
1. Full Text of Rule 18
2. Non-Viable and Derivative: Two Definitions
3. Art. 1: Which Tissue Products Does the Regulation Apply To?
4. Art. 1(8): Device Incorporating Non-Viable Human Tissue as an Integral Part
5. Annex I 13: Materials of Biological Origin
6. Indication on the Label
7. Annex IX 5.3 in Conformity Assessment
8. Two Mandatory Fields in the ÜTS Product Record
9. Frequently Asked Questions
1. Full Text of Rule 18
Annex VIII, Section 7, Special Rules (unofficial translation):
“7.5. Rule 18 All devices manufactured utilising non-viable or rendered non-viable tissues or cells of human or animal origin, or their derivatives, are classified as class III, with the exception of devices manufactured utilising non-viable or rendered non-viable tissues or cells of animal origin, or their derivatives, that are intended to come into contact with intact skin only.”
Result: devices within the scope of the rule are class III.
The exception is only for devices of animal origin, and its condition is that the device is intended to come into contact with intact skin only.
No exception is written for devices using tissue, cells or derivatives of human origin.
If more than one rule applies to the same device, the application rule 3.5 of Annex VIII applies:
“3.5. If several rules, or within the same rule several sub-rules, apply to the same device based on the device's intended purpose, the strictest rule and sub-rule resulting in the higher classification shall apply.”
For all the classification rules, see our page on medical device classification rules.
2. Non-Viable and Derivative: Two Definitions
Definitions in Article 3 of the Regulation:
“f) Non-viable: Having no potential for metabolism or multiplication,”
“ggg) Derivative: A non-cellular substance extracted from human or animal tissues or cells through a manufacturing process and therefore containing no cells or tissue,”
3. Art. 1: Which Tissue Products Does the Regulation Apply To?
Under the third paragraph of Article 1, the Regulation applies to the following devices:
“c) Devices manufactured utilising non-viable or rendered non-viable tissues or cells of animal origin, or their derivatives,”
“ç) Devices manufactured utilising derivatives of non-viable or rendered non-viable tissues or cells of human origin”
Under the fourth paragraph, it does not apply to the following products:
“e) Transplants, tissues or cells of animal origin, or their derivatives, or products containing or consisting of them, except for devices manufactured utilising non-viable or rendered non-viable tissues or cells of animal origin, or their derivatives,”
“f) Transplants, tissues or cells of human origin, or their derivatives, or products containing or consisting of them, falling within the scope of the Regulation on the Quality and Safety of Human Tissues and Cells and Related Centers, dated 27/10/2010 and numbered 27742, except for devices manufactured utilising derivatives of non-viable or rendered non-viable tissues or cells of human origin,”
On the animal side, non-viable tissues, cells and derivatives are within scope. On the human side, subparagraph (ç) lists only derivatives of non-viable tissues and cells; subparagraph (f) excludes human-origin transplants, tissues and cells other than these devices. For products outside the scope, see our article on products excluded from the MDR.
4. Art. 1(8): Device Incorporating Non-Viable Human Tissue as an Integral Part
“(8) Devices that, when placed on the market or put into service, incorporate as an integral part non-viable tissues or cells of human origin, or their derivatives, with an action ancillary to that of the device, are subject to this Regulation. In this case, the provisions of legislation on donation, procurement, testing, processing, preservation, storage and distribution also apply.”
Under the continuation of the same paragraph, if the tissues or cells do not have an ancillary action but act as the principal action and the product is not an advanced therapy medicinal product, the product is subject to the legislation on donation, procurement, testing, processing, preservation, storage and distribution. For the boundary between drugs and devices, see our article on borderline products.
5. Annex I 13: Materials of Biological Origin
Subparagraphs (a) and (b) of item 13.1, for tissue or cell derivatives of human origin:
“a) The donation, procurement and testing of tissues and cells shall be done in accordance with the Regulation on the Quality and Safety of Human Tissues and Cells and Related Centers,”
“b) The processing, preservation and any other handling of those tissues and cells, or of their derivatives, shall be carried out so as to provide safety for patients, users and, where applicable, other persons. In particular, safety with regard to viruses and other transmissible agents shall be addressed by appropriate methods of sourcing and by implementation of validated methods of elimination or inactivation in the course of the manufacturing process,”
Item 13.2, for tissues, cells or derivatives of animal origin:
“a) Where applicable, taking into account the animal species, tissues and cells of animal origin, or their derivatives, shall originate from animals that have been subjected to veterinary controls that are adapted to the intended use of the tissues. Information on the geographical origin of the animals shall be retained by manufacturers,”
“b) The sourcing, processing, preservation, testing and handling of tissues, cells and substances of animal origin, or their derivatives, shall be carried out so as to provide safety for patients, users and, where applicable, other persons. In particular safety with regard to viruses and other transmissible agents shall be addressed by implementation of validated methods of elimination or viral inactivation in the course of the manufacturing process, except where the use of such methods would lead to unacceptable degradation compromising the clinical benefit of the device.”
“c) (Amended: OG-29/7/2022-31907) For devices manufactured utilising tissues or cells of animal origin, or their derivatives, as referred to in the Regulation on Medical Devices Manufactured Utilising Tissues of Animal Origin published in the Official Gazette dated 14/1/2021 and numbered 31364, the particular requirements laid down in that Regulation apply.”
Item 13.3 sets a separate provision for non-viable biological substances other than human or animal tissue:
“13.3. For devices manufactured utilising non-viable biological substances other than those referred to in items 13.1 and 13.2 of this Annex, the processing, preservation, testing and handling of those substances, including waste disposal, shall be carried out so as to provide safety for patients, users and, where applicable, other persons.”
6. Indication on the Label
One of the pieces of information on the label under item 23.2 of Annex I:
“d) Where applicable, an indication that the device contains or incorporates:”
“- Tissues or cells of human origin, or their derivatives, or”
“- Tissues or cells of animal origin, or their derivatives, as specified in the Regulation on Medical Devices Manufactured Utilising Tissues of Animal Origin (Amended wording: OG-2/4/2023-32151),”
For the other contents of the label, see our article on Turkish label and instructions for use.
7. Annex IX 5.3 in Conformity Assessment
Item 5.3 of Annex IX regulates the additional procedure the notified body follows for these devices. Item 5.3.1, for human-origin derivatives:
“b) Within 120 days of receipt of all the required documentation, the competent authority for human tissues and cells gives its opinion to the notified body.”
“The notified body shall not issue the certificate if the scientific opinion is unfavourable.”
Item 5.3.2, for animal-origin tissues, states that the notified body applies the relevant requirements of the Regulation on Medical Devices Manufactured Utilising Tissues of Animal Origin. For the notified body process, see our article on choosing the conformity assessment procedure.
8. Two Mandatory Fields in the ÜTS Product Record
Field for tissue of human origin in guidance TCKKD-KLVZ-03:
“v) Does it contain tissues or cells of human origin or their derivatives?:”
“1) This field is mandatory to select in ÜTS.”
“3) If the device contains tissues or cells of human origin or their derivatives, this information must be on the label and/or sales packaging and in the instructions for use, and this field must be selected as "Yes".”
Field for tissue of animal origin:
“y) Does it contain tissues or cells of animal origin or their derivatives, per (EU) 722/2012?:”
“1) This field is mandatory to select in ÜTS.”
“3) If the device contains tissues or cells of animal origin or their derivatives, this information must be on the label and/or sales packaging and in the instructions for use, and this field must be selected as "Yes".”
“4) If the device contains tissues or cells of animal origin or their derivatives, this device, except for devices intended to come into contact with intact skin only, is a Class-III medical device under the classification rule referred to in MDR Annex VIII and in subparagraph (d) of the sixth paragraph of Article 56 of this Guidance”
For the documents required in ÜTS for Class III devices, see our article on Class III medical devices, and for the registration steps, ÜTS medical device product registration.
9. Frequently Asked Questions
Which class is a device within the scope of Rule 18?
Class III under Rule 18 of Annex VIII. Only devices of animal origin intended to come into contact with intact skin only are outside this rule.
Does the intact skin exception also apply to human-origin derivatives?
No. The exception in Rule 18 is written only for devices manufactured utilising non-viable or rendered non-viable tissues, cells and derivatives of animal origin.
Is a human tissue transplant product subject to the Medical Device Regulation?
Under subparagraph (f) of the fourth paragraph of Article 1, transplants, tissues and cells of human origin are outside the scope of the Regulation, except for devices manufactured utilising non-viable human tissue or cell derivatives.
Who retains the information on the geographical origin of the animal?
Under Annex I 13.2(a), the manufacturer retains information on the geographical origin of the animals.
Where is tissue content entered in ÜTS?
Under TCKKD-KLVZ-03, the product record has two separate mandatory fields, for human-origin and animal-origin tissue. If the device contains this material, "Yes" is selected and the information appears on the label and/or sales packaging and in the instructions for use.
For ÜTS registration of your device containing tissue or derivatives: Medical Device ÜTS Registration Consultancy
Sources



